Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
(2018), Cell Metab 27(3), PubMed 29514064 Statistics from preclinical literature NAD+ (nicotinamide adenine dinucleotide), a key cofactor of redox reactions and substrate for sirtuins, PARP, CD38 , molecular weight 663.43 g/mol (not a peptide, but traditionally included in peptide research collections) Identified by Arthur Harden (Nobel Prize 1929) in 1906 as a coferment Standard experimental intravenous dose in clinical studies: 250750 mg/day for 410 days (Grant 2019, Conlon & Bird 2020) NAD+ levels decline with age by ~50 % in various tissues between ages 30 and 80 (Massudi 2012) Mechanism of supplementation: direct intravenous repletion, or precursors NR (nicotinamide riboside), NMN (nicotinamide mononucleotide) that are converted to NAD+ via NAMPT/NRK enzymes In Conlon & Bird (2020, n=11): NAD+ IV infusion 750 mg/day for 6 days raised plasma NAD+ by ~40 % over baseline NR and NMN are registered in the USA as dietary supplements (NDI status)
USA 87 , 71857189 (1990)
Retatrutide Dosing Guide Clinical trial protocols, pharmacokinetics, and detailed dosing information
Embrace a future where aging is just a number, and vitality knows no bounds
it is supplied as a chemical reagent for laboratory use
US$ 29.03
US$ 21.31
US$ 27.32
US$ 23.51
